Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2022  |  Volume : 18  |  Issue : 2  |  Page : 509-515

Percutaneous microwave ablation under ultrasound guidance for renal cell carcinomas at clinical staging T1 in patients aged 65 years and older: A comparative study

1 Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China
2 Beijing Engineering Research Center of Mixed Reality and Advanced Display, School of Optics and Photonics, Beijing Institute of Technology, Beijing, China

Correspondence Address:
Ping Liang
Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.jcrt_531_22

Rights and Permissions

Objectives: To ascertain the clinical outcomes of patients aged ≥65 years with clinical staging T1 (cT1) renal cell carcinoma (RCC) treated with percutaneous microwave ablation (MWA) under ultrasound control compared with those aged <65. Materials and methods: From September 2009 to December 2016, clinical data of two groups, Group O (≥ 65 years) consisting of 75 patients (76 RCCs) and Group Y (< 65 years) consisting of 91 patients (99 RCCs), who underwent MWA treatment for RCC with comparable mean diameters at baseline, were retrospectively evaluated. The methodological effectiveness, cumulative overall survival (OS) and disease-free survival (DFS), local tumor progression (LTP), major and minor complications, and renal performance, including serum creatinine (Cr) and blood urea nitrogen (BUN) between the two categories, were statistically assessed by SPSS. Results: After excision, there were no significant differences between the two groups concerning technical efficacy, LTP, and major and minor complications. The cumulative OS and DFS rates at 1, 3, and 5 years in Group O versus Group Y were 100%, 92.6%, and 92.6% versus 98.6%, 96.9%, and 90.9% (P = 0.701), and 100%, 92.5%, and 92.5% versus 98.6%, 96.9%, and 90.4% (P = 0.697), respectively. There was no significant variance between serum Cr and BUN between the two groups before MWA and at the last follow-up. Conclusion: Due to the corresponding clinical outcomes for the treatment of cT1 RCCs in patients aged <65 years and ≥65 years, the US-guided MWA is a safe and effective method and may be suggested as one of the first-line nonsurgical options for identified older patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded18    
    Comments [Add]    

Recommend this journal